Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cellestia Biotech AG is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus. The company’s clinical lead, CB-103, has advanced to phase 2 in oncology, followed by a rich R&D pipeline of novel gene transcription factor inhibitors targeting oncology, autoimmune and inflammatory disorders.
Biotech company Fibriant has developed a unique recombinant fibrinogen manufacturing platform that is able to create a range of products that offer advantages over the plasma version.
Biotechnology company BioTheryX develops unique therapeutics for both oncology and inflammatory diseases based upon its novel protein degradation technology platform.
With its breakthrough dual-targeted natural killer cell therapy platform, ONK Therapeutics is creating its own pipeline of cell therapy candidates, and seeks to further unlock its potential through partnerships.
TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
Targeting acute respiratory distress syndrome, Tetra Bio-Pharma’s novel anti-inflammatory drug, ARDS-003, may be a treatment option for patients with COVID-19 and sepsis.
ExosomeDx harnesses biological information from exosomes for biomarker discovery and diagnostic development. The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker-related needs.
Immunological investigator, Rapid Novor, is decoding the immune response by sequencing and quantifying the antibody repertoire to provide in-depth profiling to develop personalized medicine and patient-specific treatment options.
Century Therapeutics’ deliberate, high-caliber approach to generating induced pluripotent stem cell-derived products has the potential to significantly expand the effectiveness and accessibility of cell therapies for both blood and solid cancers.
GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies based on its Vδ1+ γδ T cell platforms for the treatment of solid tumors and beyond.
Mustang Bio is developing next-generation CAR T and gene therapies for cancer and rare genetic diseases, with lead clinical programs in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and X-linked severe combined immunodeficiency.
A specialist in orally administered oncology agents, Taiho Oncology is expanding its portfolio through a growing internal pipeline of targeted therapies and a hunt to acquire new late-stage oncology assets.
